Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $85.59 -1.9%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Diginex reports 77% revenue rise but $31M net loss in FY2026
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
